4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001140361-25-046786
President & Immunovant CEO sold 275,000 shares at an average $22.47 ($6,179,750)
- President & Immunovant CEO acquired 431,689 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Venker Eric President & Immunovant CEO | 2025-12-23 | Option exercise | +313,841 | $3.85 | $1,208,288 | 1,811,749 | D |
| Venker Eric President & Immunovant CEO | 2025-12-23 | Sale | −200,000 | $22.45 | $4,490,000 | 1,611,749 | D |
| Venker Eric President & Immunovant CEO | 2025-12-24 | Option exercise | +117,848 | $3.85 | $453,715 | 1,729,597 | D |
| Venker Eric President & Immunovant CEO | 2025-12-24 | Sale | −75,000 | $22.53 | $1,689,750 | 1,654,597 | D |
| Derivatives | |||||||
| Venker Eric President & Immunovant CEO | 2025-12-23 | Option exercise · Stock Option (Right to Buy) | −313,841 | 5,562,682 | D | ||
| Venker Eric President & Immunovant CEO | 2025-12-24 | Option exercise · Stock Option (Right to Buy) | −117,848 | 5,444,834 | D | ||
| Open-market sales · 275,000 sh · avg $22.47 · $6,179,750 | |||||||
Loading xslF345X05/form4.xml…